Third Point Discloses 5.8% Stake in Strata, Calls for Review of Potential Sale
Key Facts
Third Point and Daniel Loeb disclosed joint ownership of 5,126,511 shares in Strata Critical Medical, equal to about 5.8% of its shares, in a filing they signed on October 15, 2026. The disclosure puts the investor on record calling on the company to consider strategic alternatives, including a potential sale. The investors had previously disclosed their investment on Schedule 13G on August 11, 2025, then amended it on November 14 of the same year. The shift to Schedule 13D reflects their proposals concerning the company’s strategic options, but does not include a declaration of intent to change control. Third Point said Strata’s core business is strong, but lacks the scale to justify its current general and administrative expenses.
The disclosed cost of purchasing the shares was $24,452,374, according to the filing, and Third Point said the funds used their own investment capital to complete the purchases. These shares represent the stake the investors disclosed as owning on the date the filing was submitted. The 5.8% figure was calculated based on 88,466,806 shares outstanding, the number the company reported in its quarterly report dated July 28, 2026. This basis specifies the share count the investors used to calculate their stake, while the filing states the total cost of the holding. Strata shares closed at $4.66 on October 23, 2026.
In explaining its position, Third Point said the company’s “core business is strong, but it does not have the scale to support its current general and administrative expenses.” It added that the incentive options granted to management are not aligned with shareholder value creation. Based on this view, it called on the company to explore strategic alternatives, including considering a potential sale. The filing said the sale could be managed by a reputable investment banking firm. Third Point thus linked its request to consider alternatives to its stated observations about the business’s scale, general and administrative expenses, and management incentives.
Strata operates in medical logistics services related to hospitals, organ transplant centers and organ procurement organizations, according to its quarterly report. Its business includes organ transportation, recovery and transplantation, as well as cardiovascular perfusion services. This activity places the company within an air transport and surgical services network serving healthcare and organ transplant institutions. The investors believe the strength of the core business is not enough, in their view, to justify the current general and administrative expense structure. They also said the design of management incentives is not aligned, in their view, with the goal of creating shareholder value.
The investors said they may engage with Strata’s management, board of directors and other shareholders on operational, governance and strategic matters. They also said they intend to review their investment in the company’s shares or related derivatives on an ongoing basis. The disclosure does not settle whether the company will respond to the call to consider a sale or whether any discussions will lead to a specific course of action. In trading, the stock rose 4.61% on October 16, the trading day after the disclosure was accepted by the Securities and Exchange Commission. It then closed at $4.66 on October 23, according to EL7 data.